KWM
MRNA icon

Keebeck Wealth Management’s Moderna MRNA Stock Holding History

Keebeck Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,705
Closed -$321K – 269
2024
Q2 		$321K Hold
2,705
– – 0.05% 213
2024
Q1 		$288K Buy
2,705
+185
+7% +$18.6K 0.04% 240
2023
Q4 		$251K Buy
2,520
+20
+0.8% +$1.68K 0.04% 240
2023
Q3 		$258K Hold
2,500
– – 0.05% 225
2023
Q2 		$304K Sell
2,500
-31
-1% -$4.13K 0.04% 213
2023
Q1 		$389K Buy
2,531
+24
+1% +$3.96K 0.06% 182
2022
Q4 		$450K Buy
2,507
+7
+0.3% +$1.15K 0.08% 166
2022
Q3 		$296K Hold
2,500
– – 0.06% 189
2022
Q2 		$357K Sell
2,500
-430
-15% -$61.5K 0.07% 178
2022
Q1 		$505K Hold
2,930
– – 0.08% 160
2021
Q4 		$744K Hold
2,930
– – 0.13% 122
2021
Q3 		$1.13M Sell
2,930
-200
-6% -$73.8K 0.22% 95
2021
Q2 		$735K Hold
3,130
– – 0.11% 135
2021
Q1 		$410K Hold
3,130
– – 0.06% 175
2020
Q4 		$327K Hold
3,130
– – 0.06% 174
2020
Q3 		$221K Buy
+3,130
New +$218K 0.05% 173

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Keebeck Wealth Management's MRNA Position: Q3 2024 in Review

Keebeck Wealth Management sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,705 shares — an estimated $321K sold.

Keebeck Wealth Management first reported a position in MRNA in Q3 2020 and held it in 16 quarters. The position peaked at $1.13M in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Keebeck Wealth Management reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Keebeck Wealth Management sold 2,705 Moderna shares in Q3 2024, an estimated $321K.
  • Keebeck Wealth Management first reported a position in Moderna in Q3 2020 and held it in 16 quarters.
  • Keebeck Wealth Management's Moderna position peaked at $1.13M in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Keebeck Wealth Management's 13F filing for Q3 2024, filed 14 Nov 2024.